- Related Products
MedEx answers any queries you might have regarding Eribulin purchase, shipping and payment terms.
Feel free to contact support through inquiry form, MedeEx is fully dedicated towards your needs 24/7.
Eribulin is a new drug in the treatment of breast cancer.
The active substance of the drug is eribulin, a compound that interferes with the synthesis and growth of tumor cells. Eribulin is an analogue of a natural substance of similar action contained in sea sponges belonging to the species Halichondria okadai.
Conducted large-scale clinical studies convincingly demonstrated the effectiveness of Eribulin in the advanced stages of breast cancer: its use significantly improved the survival of patients and their quality of life. By results of researches it has been established, that efficiency of Eribulin exceeds of other cytostatic agents almost on 20%.
Currently, Eribulin is registered for the treatment of adult patients with inoperable common or metastatic liposarcomas who have previously received anthracycline-based therapy (except when these drugs could not be prescribed) for a common or metastatic disease. Eribulin is the first drug that demonstrated a significant increase in the survival rate of patients with this type of soft tissue sarcoma.
Pharmacodynamic of Eribulin:
By means of an antimitotic mechanism, it blocks the cell cycle in G2 / M phases (GAP 2 / mitosis cell cycle stages) and leads to a disturbance in the formation of mitotic spindles, which leads to apoptotic cell death as a result of prolonged blockage of mitosis.
It inhibits the growth phase of microtubules, without affecting the shortening phase, as a result of which tubulin aggregates that do not have functional activity are formed.
Pharmacokinetics of Eribulin:
After intravenous administration, the bond with plasma proteins is 49-65%.
Metabolism in the liver. Half-life is 40 hours. Elimination through the intestine and kidneys.
Indications of Eribulin:
Monotherapy in patients with locally advanced or metastatic breast cancer previously received at least two different regimens of chemotherapy for a common disease.
Prior therapy should include anthracyclines and taxanes, excluding those patients who could not be prescribed these remedies.